Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
LORCH, Anja
PEACE6-Unfit, NCT04916613 / 2020-003663-26: ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)	Recruiting	3	300	Europe	Darolutamide 300 mg, Nubeqa®, Placebo, Androgen deprivation therapy, ADT	UNICANCER, Bayer	Prostate Cancer Metastatic	03/28	09/37
SAKK 08/23, NCT06401980: Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)	Recruiting	2	162	Europe	Darolutamide, Nubeqa®, Standard of care	Swiss Group for Clinical Cancer Research	Metastatic Castration-resistant Prostate Cancer	09/29	12/29
SAKK 06/19, NCT04630730: Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC	Recruiting	2	46	Europe	Recombinant intravesical BCG (Bacillus Calmette-Guérin VPM1002BC), VPM1002BC, Atezolizumab, Tecentriq™, Cisplatin, Platinol®, Gemcitabine, Gemzar ®	Swiss Group for Clinical Cancer Research	Bladder Cancer	06/26	06/30
SAKK 01/18, NCT03937843 / 2019-000514-11: Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma	Active, not recruiting	2	135	Europe	Carboplatin, Cisplatin, Etoposide	Swiss Group for Clinical Cancer Research, German Testicular Cancer Study Group	Seminoma, Testicular Cancer	12/26	12/46